BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lichen Planopilaris readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Lichen Planopilaris\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07532603-1450@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lisraya (brepocitinib): Phase 2/3 readout est. (NCT07532603)
DESCRIPTION:Lisraya (brepocitinib)\, phase 2/3\, Lichen Planopilaris.\nStud
 y: A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris\nE
 stimated primary completion: 31 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/brepocitinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07532603
URL:https://assetmemo.bio/drug/brepocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
